SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SAN RAMON, Calif., Feb. 26, 2016 -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its fourth quarter and year end 2015 financial results and provide a corporate update on Thursday, March 10, 2016, after the close of the financial markets. The company will host a conference call folllowing the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.
The live webcast will include slides that can be accessed on the Company's website under the Investors section/Events and Presentations: http://investors.galenabiopharma.com/events.cfm. The conference call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 50939696. The archived webcast replay will be available on the Company's website for 90 days.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
